Catheter lock solution taurolidine, heparin and citrate

Neutrolin

  • Prevents thrombosis1
  • Protects against infection1

Neutrolin®

First-in-class, non-antibiotic solution that prevents infections and thrombosis associated with central venous catheters.

  • Neutrolin® consists of taurolidine 1.35 %, heparin 1,000 units/mL and citrate 3.5 %:
    • Taurolidine 1.35 % is a synthetic broad-spectrum anti-bacterial and anti-fungal compound that is metabolized to the amino acid taurine in humans, which limits its  toxicity for clinical use
    • Heparin 1,000 units/mL is added to Neutrolin as a well-established anticoagulant
    • Citrate 3.5 % is added as a buffer to ensure that taurolidine remains in solution at ~ pH 6
  • Neutrolin® is an antimicrobial and anticoagulant catheter lock solution for hemodialysis patients
  • Neutrolin® provides protection against catheter-related blood stream infections (CRBSI) and helps  to maintain catheter patency

Attributes of Neutrolin® which improve lock effectiveness2:

  • Broad-spectrum antimicrobial effect against bacteria and fungi
  • Safe and compatible with tissue and blood
  • No evidence of bacterial resistance in human
  • No systemic pharmacological effect
  • Inactivation of endotoxin
  • Reduces adherence of bacteria and blood to surfaces


Active ingredient – taurolidine

  • Taurolidine is a unique nontoxic substance that eliminates binding of bacteria and some fungi  to the surface
  • Taurolidine is NOT an antibiotic and it has never demonstrated bacterial resistance
  • Taurolidine is a broad-spectrum antimicrobial active substance against virulent bacteria and fungi,  responsible for most HD infections
  • Taurolidine has proven effective in preventing catheter colonization at the planktonic level  and eradication of a developed biofilm in several types of in vitro tests

Order now!

Any questions? Please give us a call.

Sales representant request

Download instructions of use

Download information for dialysis efficiency

1) CDC Guidelines for the Prevention of Intravascular Catheter Related Infections; 2) O`Grady et al., 2011; Morris P, Knechtle SJ. Kidney Transplantation - Principles and Practice. Saunders, 2013. 3) Napalkov P, Felici DM, Chu LK, Jacobs JR, Begelman SM. Incidence of catheter-related complications in patients with central venous or hemodialysis catheters: a health care claims database analysis. BMC Cardiovasc Disord. 2013 Oct 16;13:86. doi: 10.1186/1471-2261-13-86. PubMed PMID: 24131509; PubMed Central PMCID: PMC4015481 4) Quarello F, Forneris G. Prevention of hemodialysis catheter-related bloodstream infection using an antimicrobial lock. Blood Purif. 2002;20(1): 87-92. Review. PubMed PMID: 11803164. 5) Napalkov P, Felici DM, Chu LK, Jacobs JR, Begelman SM. Incidence of catheter-related complications in patients with central venous or hemodialysis catheters: a health care claims database analysis. BMC Cardiovasc Disord. 2013 Oct 16;13:86. doi: 10.1186/1471-2261-13-86. PubMed PMID: 24131509; PubMed Central PMCID: PMC4015481